1. Pink Sheet
  2. >>Geography
  3. >>Europe

Roche Follow-On Development Strategy Highlighted By Strong 1H Results

 
• By Sten Stovall

Top oncology specialist Roche’s second quarter saw robust sales growth with new breast cancer medicines Perjeta and Kadcyla selling well, highlighting and further validating its strategy to develop follow-on drugs to replace or renew older treatments while expanding into new disease areas.

Roche extended its strong run into the second quarter of 2013, driven by its existing portfolio of cancer drugs like Avastin (bevacizumab), Lucentis (ranibizumab) and Herceptin (trastuzumab), recently launched cancer medicines Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine) and continued growth in the group’s clinical laboratory business, CEO Severin Schwan told an investor call July 25.

He promised Roche will keep coming up with new cutting-edge products, adding: “We will continue to focus on innovation with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.